Brown E - Search Results

1

Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.

Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ. Brown E, et al. Obes Rev. 2019 Jun;20(6):816-828. doi: 10.1111/obr.12841. Epub 2019 Apr 10. Obes Rev. 2019. PMID: 30972878 Review.

2

Multidisciplinary management of refractory insulinomas.

Brown E, Watkin D, Evans J, Yip V, Cuthbertson DJ. Brown E, et al. Clin Endocrinol (Oxf). 2018 May;88(5):615-624. doi: 10.1111/cen.13528. Epub 2018 Mar 2. Clin Endocrinol (Oxf). 2018. PMID: 29205458 Review.

3

Newer GLP-1 receptor agonists and obesity-diabetes.

Brown E, Cuthbertson DJ, Wilding JP. Brown E, et al. Peptides. 2018 Feb;100:61-67. doi: 10.1016/j.peptides.2017.12.009. Peptides. 2018. PMID: 29412833 Review.

4

Longitudinal analysis of risk of non-alcoholic fatty liver disease in adulthood.

Cuthbertson DJ, Brown E, Koskinen J, Magnussen CG, Hutri-Kähönen N, Sabin M, Tossavainen P, Jokinen E, Laitinen T, Viikari J, Raitakari OT, Juonala M. Cuthbertson DJ, et al. Among authors: brown e. Liver Int. 2019 Jun;39(6):1147-1154. doi: 10.1111/liv.13993. Epub 2019 Apr 11. Liver Int. 2019. PMID: 30347485 Free article.

5

A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors.

Brown E, Rajeev SP, Cuthbertson DJ, Wilding JPH. Brown E, et al. Diabetes Obes Metab. 2019 Apr;21 Suppl 2:9-18. doi: 10.1111/dom.13650. Diabetes Obes Metab. 2019. PMID: 31081592 Review.

6

Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.

Hydes TJ, Summers N, Brown E, Alam U, Thomaides-Brears H, Wilding JPH, Cuthbertson DJ. Hydes TJ, et al. Among authors: brown e. Diabet Med. 2020 Nov;37(11):1793-1806. doi: 10.1111/dme.14356. Epub 2020 Jul 13. Diabet Med. 2020. PMID: 32619031 Review.

7

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.

Brown E, Wilding JPH, Alam U, Barber TM, Karalliedde J, Cuthbertson DJ. Brown E, et al. Ann Med. 2021 Dec;53(1):2072-2089. doi: 10.1080/07853890.2020.1841281. Ann Med. 2021. PMID: 33107349 Free PMC article. Review.

8

The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review.

Eleftheriadou A, Williams S, Nevitt S, Brown E, Roylance R, Wilding JPH, Cuthbertson DJ, Alam U. Eleftheriadou A, et al. Among authors: brown e. Diabetologia. 2021 Feb;64(2):288-303. doi: 10.1007/s00125-020-05316-z. Epub 2020 Nov 9. Diabetologia. 2021. PMID: 33164108 Free PMC article.

9

Prevalence of peripheral neuropathy in pre-diabetes: a systematic review.

Kirthi V, Perumbalath A, Brown E, Nevitt S, Petropoulos IN, Burgess J, Roylance R, Cuthbertson DJ, Jackson TL, Malik RA, Alam U. Kirthi V, et al. Among authors: brown e. BMJ Open Diabetes Res Care. 2021 May;9(1):e002040. doi: 10.1136/bmjdrc-2020-002040. BMJ Open Diabetes Res Care. 2021. PMID: 34006607 Free PMC article. Review.

10

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.

Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. Brown E, et al. Lancet. 2021 Jul 17;398(10296):262-276. doi: 10.1016/S0140-6736(21)00536-5. Epub 2021 Jun 30. Lancet. 2021. PMID: 34216571 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,314 results

Search Page

Filters